Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios.
Herceptin (trastuzumab) is an adjuvant chemotherapy agent used in treatment of certain breast cancers. Limited information is available on the use of herceptin in pregnancy. This case is a twin pregnancy exposed to herceptin until 23 weeks' gestation. One twin had chronic renal failure develop, whereas the other twin did not.
Beale
Jennifer M A
JM
Wellington Hospital, Obstetrics and Gynaecology, Wellington, New Zealand. jmab_12@hotmail.com
Tuohy
Jeremy
J
McDowell
Simon J
SJ
D000328:Adult; D000653:Amniotic Fluid / Q000187:drug effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D003404:Creatinine / Q000097:blood; D004200:Diseases in Twins / Q000139:chemically induced; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007676:Kidney Failure, Chronic / Q000097:blood / Q000139:chemically induced; D016104:Oligohydramnios / Q000453:epidemiology*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011272:Pregnancy, Multiple; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003404:Creatinine; D000068878:Trastuzumab